AVICANNA INC (AVCN.CA) Stock Price, Forecast & Analysis
Canada • Toronto Stock Exchange • TSX:AVCN • CA05368K1003
AVCN.CA Key Statistics, Chart & Performance
The current stock price of AVCN.CA is 0.18 CAD. In the past month the price decreased by -21.74%. In the past year, price decreased by -25%.
AVCN.CA Technical Analysis
AVCN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AVCN.CA. AVCN.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AVCN.CA Financial Highlights
Over the last trailing twelve months AVCN.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 77.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.87% | ||
| ROE | -60.37% | ||
| Debt/Equity | 0 |
AVCN.CA Forecast & Estimates
AVCN.CA Ownership
AVCN.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.44 | 3.1B | ||
| GSD | DEVONIAN HEALTH GROUP INC | N/A | 1.659B | ||
| CRON | CRONOS GROUP INC | 37.46 | 1.39B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.234B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.02 | 887.271M | ||
| GUD | KNIGHT THERAPEUTICS INC | 122.36 | 582.832M | ||
| WEED | CANOPY GROWTH CORP | N/A | 549.005M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 397.224M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 27.01 | 366.343M | ||
| TSND | TERRASCEND CORP | N/A | 316.695M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About AVCN.CA
Company Profile
Avicanna, Inc. is a medical cannabis company, which intends to engage in the business of discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-18. The company focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Company Info
AVICANNA INC
480 University Avenue, Suite 1502
TORONTO ONTARIO M5G 1V2 CA
CEO: Aras Azadian
Employees: 38
Phone: 16472435283
AVICANNA INC / AVCN.CA FAQ
What does AVICANNA INC do?
Avicanna, Inc. is a medical cannabis company, which intends to engage in the business of discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-18. The company focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Can you provide the latest stock price for AVICANNA INC?
The current stock price of AVCN.CA is 0.18 CAD. The price increased by 5.88% in the last trading session.
Does AVICANNA INC pay dividends?
AVCN.CA does not pay a dividend.
How is the ChartMill rating for AVICANNA INC?
AVCN.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of AVICANNA INC (AVCN.CA) based on its PE ratio?
AVICANNA INC (AVCN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).
Would investing in AVICANNA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AVCN.CA.
What is the next earnings date for AVCN stock?
AVICANNA INC (AVCN.CA) will report earnings on 2026-03-30, after the market close.